Logo image of ZBH

ZIMMER BIOMET HOLDINGS INC (ZBH) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:ZBH - US98956P1021 - Common Stock

85.99 USD
-1.33 (-1.52%)
Last: 1/27/2026, 5:05:00 PM
85.99 USD
0 (0%)
After Hours: 1/27/2026, 5:05:00 PM

ZBH Key Statistics, Chart & Performance

Key Statistics
Market Cap17.04B
Revenue(TTM)8.01B
Net Income(TTM)805.20M
Shares198.18M
Float197.86M
52 Week High114.44
52 Week Low85.33
Yearly Dividend0.97
Dividend Yield1.04%
EPS(TTM)8.09
PE10.63
Fwd PE10.02
Earnings (Next)02-10
IPO2001-07-25
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
ZBH short term performance overview.The bars show the price performance of ZBH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10

ZBH long term performance overview.The bars show the price performance of ZBH in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of ZBH is 85.99 USD. In the past month the price decreased by -5.27%. In the past year, price decreased by -21.46%.

ZIMMER BIOMET HOLDINGS INC / ZBH Daily stock chart

ZBH Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ZBH Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ZBH. ZBH has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZBH Financial Highlights

Over the last trailing twelve months ZBH reported a non-GAAP Earnings per Share(EPS) of 8.09. The EPS increased by 2.53% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.05%
ROA 3.43%
ROE 6.31%
Debt/Equity 0.59
Chartmill High Growth Momentum
EPS Q2Q%9.2%
Sales Q2Q%9.71%
EPS 1Y (TTM)2.53%
Revenue 1Y (TTM)5.47%

ZBH Forecast & Estimates

33 analysts have analysed ZBH and the average price target is 104.24 USD. This implies a price increase of 21.22% is expected in the next year compared to the current price of 85.99.

For the next year, analysts expect an EPS growth of 3.17% and a revenue growth 7.04% for ZBH


Analysts
Analysts67.88
Price Target104.24 (21.22%)
EPS Next Y3.17%
Revenue Next Year7.04%

ZBH Ownership

Ownership
Inst Owners100.37%
Ins Owners0.13%
Short Float %5.22%
Short Ratio4.44

ZBH Latest News, Press Relases and Analysis

About ZBH

Company Profile

ZBH logo image Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

Company Info

ZIMMER BIOMET HOLDINGS INC

345 E Main St

Warsaw Indiana INDIANA 46580 US

CEO: Bryan Hanson

Employees: 17000

ZBH Company Website

ZBH Investor Relations

Phone: 15742676131

ZIMMER BIOMET HOLDINGS INC / ZBH FAQ

Can you describe the business of ZIMMER BIOMET HOLDINGS INC?

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.


Can you provide the latest stock price for ZIMMER BIOMET HOLDINGS INC?

The current stock price of ZBH is 85.99 USD. The price decreased by -1.52% in the last trading session.


Does ZBH stock pay dividends?

ZIMMER BIOMET HOLDINGS INC (ZBH) has a dividend yield of 1.04%. The yearly dividend amount is currently 0.97.


How is the ChartMill rating for ZIMMER BIOMET HOLDINGS INC?

ZBH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is ZIMMER BIOMET HOLDINGS INC (ZBH) stock traded?

ZBH stock is listed on the New York Stock Exchange exchange.


What is the employee count for ZBH stock?

ZIMMER BIOMET HOLDINGS INC (ZBH) currently has 17000 employees.


Can you provide the short interest for ZBH stock?

The outstanding short interest for ZIMMER BIOMET HOLDINGS INC (ZBH) is 5.22% of its float.